Biosimilar
FDA Approves Fourth Ustekinumab Biosimilar, Otulfi
The FDA has approved ustekinumab-aauz (Otulfi, Fresenius Kabi/Formycon), a biosimilar to ustekinumab (Stelara, ...
OCTOBER 7, 2024
Will Humira Biosimilars Cause a Wave or a Ripple?
With 2023 poised to be the year of the adalimumab biosimilar wave, a new report focuses on market expansion and ...
JUNE 8, 2023
SubQ Infliximab Holds Up Against IV Form for IBD
Patients with inflammatory bowel disease are one step closer to having a subcutaneous version of infliximab.
SEPTEMBER 9, 2020
FDA Approves Adalimumab Biosimilar
The FDA has approved adalimumab-bwwd (Hadlima, Samsung Bioepis Co.), a biosimilar referencing adalimumab (Humira, ...
JULY 31, 2019
Biosimilar Agent Encouraging in IBD Trial
A biosimilar of infliximab appeared to perform as well as the originator drug for the treatment of inflammatory ...
APRIL 10, 2018
